Latest news and research on all cancers and treatments, updated several times a week
“The puzzle has hampered efforts to harness the immune system to fight disease. Working in the laboratory and in mouse models of cancer, ...
The cells in that blood are then engineered and reprogrammed so they can better fight off cancer, to boost your immune system. The blood is then put ...
The adjuvant can now be used for the first time for all preventive and therapeutic applications, for example in cancers, especially pancreatic cancer, ...
“Nuvilex's treatment for pancreatic cancer involves the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ...
Novel Therapies in Mantle Cell Lymphoma: A Pathway to Chemotherapy-Free Strategies
This review will cover innovative therapeutic approaches in relapsed or refractory MCL, many of which have the potential to alter treatment paradigms toward the development of strategies that do not involve conventional chemotherapy agents.
This review will cover innovative therapeutic approaches in relapsed or refractory MCL, many of which have the potential to alter treatment paradigms toward the development of strategies that do not involve conventional chemotherapy agents.
The Place of Transplantation in Mantle Cell Lymphoma
The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemo-sensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.
The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemo-sensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.
Bladder Cancer Survival Similar With Laparoscopic, Open Surgery
Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.
Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.
FDA Approves Lanreotide Injection for GEP-NETs
The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
In the past, studies have also shown increased risk for esophageal and pancreatic cancers correlated with soda consumption, as well as an increased ...
Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine ...
Inovio (NASDAQ: INO) of Plymouth Meeting, Pa., is testing its new drug candidate, called INO-1400, in adults with breast, lung, or pancreatic cancer at ...
Higher levels of cancer-causing chemicals called tobacco-specific nitrosamines ... Pancreatic cancer has also been linked to smokeless tobacco use.
Fats in blood and on the body increase men's prostate cancer risk, two ... esophageal cancer, kidney cancer, gallbladder cancer, and pancreatic ...
It was approved for additional indications of “postoperative adjuvant chemotherapy for colon cancer” in 2009 and “pancreatic cancer, which is not ...
Dr. J. Joseph Kim, President and CEO, said, "We are enthusiastic about the potential use of INO-1400cancer immunotherapy in multiple major ...
Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer - News-Medical.net
... as immunotherapy. More than 400 kinds are currently undergoing testing in clinical trials. Although they're very effective at clearing out cancer cells, ...
Cancer News in Science Daily
“A study has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. The results mark a turning point in cancer immunology and provide the foundation for developing more effective immunotherapies.
“Scientists have built a computer model that has uncovered disease-causing mutations in large regions of the genome that previously could not be explored. Their method seeks out mutations that cause changes in 'gene splicing,' and has revealed unexpected genetic determinants of autism, colon cancer and spinal muscular atrophy.
Tambahkan Komentar